Equity Overview
Price & Market Data
Price: $1.55
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $57,195,464
Daily Volume: 0
Performance Metrics
1 Week: 8.39%
1 Month: -1.19%
3 Months: -19.69%
6 Months: -24.76%
1 Year: -55.60%
YTD: -42.28%
Company Details
Employees: 123
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.